Strategies for Maximising Survival: Advances in High-Risk* Acute Myeloid Leukaemia (AML)

Back to resources

This Continuing Professional Development (CPD) accredited webinar gives an overview of the current AML landscape and provides insights from evidence-based practice on managing patients with AML.

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Ambulatory care AML Landscape Cytogenetics Vyxeos Liposomal Data

FOOTNOTES

*High-risk AML is defined as therapy-related AML or AML with myelodysplasia-related changes.

ABBREVIATIONS

AML, acute myeloid leukaemia; CPD, Continuing Professional Development.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100054 | May 2021